Endometriosis affects millions of people - and this new breakthrough treatment could be a game-changer for some

Ryeqo drug is hailed as a ‘potential step-change’ in how endometriosis is treated A new pill designed to transform the treatment of endometriosis has been approved for use on the NHS in England and Wales.

Gedeon Richter's drug is the only licensed GnRH antagonist option and, unlike GnRH agonists like Takeda's Prostap (leuprorelin acetate) and AstraZeneca's Zoladex (goserelin acetate) – which are only licensed for up to six months – can be taken up until menopause.

Ryeqo is likely to start being prescribed to patients in Wales within two months, but there will be restrictions on who can access it

The National Health Service (NHS) in England has approved Gedeon Richter’s Ryeqo (relugolix + estradiol + norethisterone), the first long-term pill available for endometriosis, marking a significant breakthrough in treatment.

Managing debilitating symptoms for a condition that has no cure or universal treatment is almost impossible – and it's the reality for the 1.5 million women and those born female with endometriosis in the UK.

The NHS has approved a new pill that is designed to transform the treatment of endometriosis. The combination drug will help around 1,000 women every year in England who suffer from the debilitating condition.